The association of clinicopathologic features and peripheral blood parameters with high PD-L1 expression in non-small cell lung cancer

YILMAZ, ÜLKÜ; BILGIN, BURAK; Yücel, Şebnem; Akinci, Muhammed Bulent; Sendur, Mehmet; yalcin, bulent; Hizal, Mutlu; Akyurek, Nalan

doi:10.5578/tt.69182

The association of clinicopathologic features and peripheral blood parameters with high PD-L1 expression in non-small cell lung cancer

Burak BİLGİN, (Sağlık Bilimleri Üniversitesi, Ankara Atatürk Göğüs Hastalıkları ve Göğüs Cerrahisi Eğitim ve Araştırma Hastanesi, Medikal Onkoloji Kliniği, Ankara, Türkiye)

Mutlu HİZAL, (Yıldırım Beyazıt Üniversitesi, Tıp Fakültesi, Medikal Onkoloji Bilim Dalı, Ankara, Türkiye)

Şebnem YÜCEL, (Sağlık Bilimleri Üniversitesi, Ankara Atatürk Göğüs Hastalıkları ve Göğüs Cerrahisi Eğitim ve Araştırma Hastanesi, Medikal Onkoloji Kliniği, Ankara, Türkiye)

Mehmet ŞENDUR, (Yıldırım Beyazıt Üniversitesi, Tıp Fakültesi, Medikal Onkoloji Bilim Dalı, Ankara, Türkiye)

Nalan AKYÜREK, (Gazi Üniversitesi, Tıp Fakültesi, Patoloji Anabilim Dalı, Ankara, Türkiye)

Muhammed Bülent AKINCI, (Yıldırım Beyazıt Üniversitesi, Tıp Fakültesi, Medikal Onkoloji Bilim Dalı, Ankara, Türkiye)

Ülkü YILMAZ, (Sağlık Bilimleri Üniversitesi, Ankara Atatürk Göğüs Hastalıkları ve Göğüs Cerrahisi Eğitim ve Araştırma Hastanesi, Göğüs Hastalıkları Kliniği, Ankara, Türkiye)

Bülent YALÇIN (Yıldırım Beyazıt Üniversitesi, Tıp Fakültesi, Medikal Onkoloji Bilim Dalı, Ankara, Türkiye)

Tüberküloz ve Toraks

8 0

Yıl: 2020 Cilt: 68 Sayı: 2 Sayfa Aralığı: 118 - 125 Metin Dili: İngilizce DOI: 10.5578/tt.69182 İndeks Tarihi: 22-11-2020

The association of clinicopathologic features and peripheral blood parameters with high PD-L1 expression in non-small cell lung cancer

Öz:

Introduction: Programmed death ligand 1 (PD-L1) is a marker that widelyused for prediction of response to immunotherapy. Dynamic alteration ofPD-L1 expression are the major problems for reflection of the actual status ofthe PD-L1. So, we aimed to investigate the factors that may be associated withPD-L1 expression in lung cancer.Materials and Methods: The patients diagnosed with non-small cell lung cancer were enrolled, retrospectively. The patients were stratified according toPD-L1 expression level as ≥ 50% and < 50%.Results: Totally, 217 patients were enrolled. The clinicopathologic featureswere similar between two groups, except the amount of cigarette consumption. Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and systemicimmune-inflammmotry index were found significantly lower in PD-L1 ≥ 50%(p< 0.001, p= 0.006 and p= 0.003, respectively) and also negatively correlated with PD-L1 level (rho= -0.255, p< 0.001; rho= -0.17, p= 0.013; rho= -0.185, p= 0.006, respectively)Conclusion: According to the results of our study, peripheral blood parameters can be used to the prediction of the high PD-L1expression and can be used for reflection of current PD-L1 expression.

Anahtar Kelime:

Küçük hücreli dışı akciğer kanserinde yüksek PD-L1 düzeyi ile ilişkili klinikopatolojik faktörlerin ve periferik kan parametrelerinin belirlenmesi

Öz:

Giriş: “Programmed death ligand 1 (PD-L1)” immünoterapilere yanıtı predikte etmek için yaygın olarak kullanılan bir belirteçtir. Bununla birlikte PD-L1 düzeyinin dinamik değişimi gerçek zamanlı PD-L1 düzeyinin yansıtılması için büyük bir problemdir. Bu sebeple bu çalışmada akciğer kanseri tanısı olan hastalarda PD-L1 düzeyi ile ilişkili olabilecek faktörlerin saptanması amaçlanmıştır. Materyal ve Metod: Küçük hücreli dışı akciğer kanseri tanısı olan hastalar retrospektif olarak çalışmaya dahil edildi. Hastalar PD-L1 ekspresyon düzeyine göre < %50 ve ≥ %50 olmak üzere ikiye ayrıldı. Bulgular: Toplam 217 hasta çalışmaya dahil edildi. Her iki grubun sigara tüketimi dışında klinikopatolojik özellikleri benzerdi. PD-L1 düzeyi ≥ %50 olan grupta nötrofil lenfosit oranı, platelet lenfosit oranı ve sistemik immün inflamatuvar indeks anlamlı olarak daha düşük saptandı (sırasıyla; p< 0.001, p= 0.006 ve p= 0.003). Aynı zamanda bu parametreler PD-L1 ekspresyon düzeyi ile negatif korele olarak saptandı (sırasıyla, rho= -0.255, p< 0.001; rho= -0.17, p= 0.013; rho= -0.185, p= 0.006). Sonuç: Bizim çalışma sonuçlarımıza göre periferal kan parametreleri PD-L1 düzeyini predikte etmek için kullanılabilir ve böylece güncel PD-L1 ekspresyon düzeyi yansıtılabilir

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7-34.
2. Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med 2018;50:165.
3. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for firstline treatment of metastatic nonsquamous NSCLC. N Engl J Med 2018;378:2288-301.
4. Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018;378:2078-92.
5. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123-35.
6. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373:1627-39.
7. Barlesi F, Vansteenkiste J, Spigel D, Ishii H, Garassino M, de Marinis F, et al. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Lancet Oncol 2018;19:1468-79.
8. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018;379:2342-50.
9. Shen X, Zhao B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ 2018;362:k3529.
10. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375:1823-33.
11. Yi M, Jiao D, Xu H, Liu Q, Zhao W, Han X, et al. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Mol Cancer 2018;17:129.
12. Kitano A, Ono M, Yoshida M, Noguchi E, Shimomura A, Shimoi T, et al. Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer. ESMO Open 2017;2:e000150
13. Chang LC, Chen TP, Kuo WK, Hua CC. The protein expression of PDL1 is highly correlated with those of eIF2alpha and ATF4 in lung cancer. Dis Markers 2018;2018:5068701.
14. Chen Y, Zhang Y, Chai X, Gao J, Chen G, Zhang W, et al. Correlation between the expression of PD-L1 and clinicopathological features in patients with thymic epithelial tumors. Biomed Res Int 2018;2018:5830547.
15. Teixido C, Vilarino N, Reyes R, Reguart N. PD-L1 expression testing in non-small cell lung cancer. Ther Adv Med Oncol 2018;10:1758835918763493.
16. Dietel M, Savelov N, Salanova R, Micke P, Bigras G, Hida T, et al. 130O Real-world prevalence of PD-L1 expression in locally advanced or metastatic non-small cell lung cancer (NSCLC): the global, multicentre EXPRESS study. J Thorac Oncol 2018;13:S74-S75.
17. Pawelczyk K, Piotrowska A, Ciesielska U, Jablonska K, Gletzel-Plucinska N, Grzegrzolka J, et al. Role of PD-L1 expression in non-small cell lung cancer and their prognostic significance according to clinicopathological factors and diagnostic markers. Int J Mol Sci 2019;20.
18. Petrelli F, Maltese M, Tomasello G, Conti B, Borgonovo K, Cabiddu M, et al. Clinical and molecular predictors of PD-L1 expression in non-small-cell lung cancer: systematic review and meta-analysis. Clin Lung Cancer 2018;19:315- 22.
19. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in nonsmall cell lung cancer. Science 2015;348:124-8.
20. Mimura K, Teh JL, Okayama H, Shiraishi K, Kua LF, Koh V, et al. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Cancer Sci 2018;109:43-53.
21. Garcia-Diaz A, Shin DS, Moreno BH, Saco J, EscuinOrdinas H, Rodriguez GA, et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep 2017;19:1189-201.
22. Reed JM, Branigan PJ, Bamezai A. Interferon gamma enhances clonal expansion and survival of CD4+ T cells. J Interferon Cytokine Res 2008;28:611-22.
23. Yang R, Masters AR, Fortner KA, Champagne DP, YanguasCasas N, Silberger DJ, et al. IL-6 promotes the differentiation of a subset of naive CD8+ T cells into IL-21-producing B helper CD8+ T cells. J Exp Med 2016;213:2281-91.
24. Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, et al. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-toLymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer 2017;111:176-81.
25. Bagley SJ, Kothari S, Aggarwal C, Bauml JM, Alley EW, Evans TL, et al. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer 2017;106:1-7.
26. Moschetta M, Uccello M, Kasenda B, Mak G, McClelland A, Boussios S, et al. Dynamics of neutrophils-to-lymphocyte ratio predict outcomes of PD-1/PD-L1 blockade. Biomed Res Int 2017;2017:1506824.
27. Vilain RE, Menzies AM, Wilmott JS, Kakavand H, Madore J, Guminski A, et al. Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma. Clin Cancer Res 2017;23:5024-33.

APA	BILGIN B, Hizal M, Yücel Ş, Sendur M, Akyurek N, Akinci M, YILMAZ Ü, yalcin b (2020). The association of clinicopathologic features and peripheral blood parameters with high PD-L1 expression in non-small cell lung cancer. , 118 - 125. 10.5578/tt.69182
Chicago	BILGIN BURAK,Hizal Mutlu,Yücel Şebnem,Sendur Mehmet,Akyurek Nalan,Akinci Muhammed Bulent,YILMAZ ÜLKÜ,yalcin bulent The association of clinicopathologic features and peripheral blood parameters with high PD-L1 expression in non-small cell lung cancer. (2020): 118 - 125. 10.5578/tt.69182
MLA	BILGIN BURAK,Hizal Mutlu,Yücel Şebnem,Sendur Mehmet,Akyurek Nalan,Akinci Muhammed Bulent,YILMAZ ÜLKÜ,yalcin bulent The association of clinicopathologic features and peripheral blood parameters with high PD-L1 expression in non-small cell lung cancer. , 2020, ss.118 - 125. 10.5578/tt.69182
AMA	BILGIN B,Hizal M,Yücel Ş,Sendur M,Akyurek N,Akinci M,YILMAZ Ü,yalcin b The association of clinicopathologic features and peripheral blood parameters with high PD-L1 expression in non-small cell lung cancer. . 2020; 118 - 125. 10.5578/tt.69182
Vancouver	BILGIN B,Hizal M,Yücel Ş,Sendur M,Akyurek N,Akinci M,YILMAZ Ü,yalcin b The association of clinicopathologic features and peripheral blood parameters with high PD-L1 expression in non-small cell lung cancer. . 2020; 118 - 125. 10.5578/tt.69182
IEEE	BILGIN B,Hizal M,Yücel Ş,Sendur M,Akyurek N,Akinci M,YILMAZ Ü,yalcin b "The association of clinicopathologic features and peripheral blood parameters with high PD-L1 expression in non-small cell lung cancer." , ss.118 - 125, 2020. 10.5578/tt.69182
ISNAD	BILGIN, BURAK vd. "The association of clinicopathologic features and peripheral blood parameters with high PD-L1 expression in non-small cell lung cancer". (2020), 118-125. https://doi.org/10.5578/tt.69182

APA	BILGIN B, Hizal M, Yücel Ş, Sendur M, Akyurek N, Akinci M, YILMAZ Ü, yalcin b (2020). The association of clinicopathologic features and peripheral blood parameters with high PD-L1 expression in non-small cell lung cancer. Tüberküloz ve Toraks, 68(2), 118 - 125. 10.5578/tt.69182
Chicago	BILGIN BURAK,Hizal Mutlu,Yücel Şebnem,Sendur Mehmet,Akyurek Nalan,Akinci Muhammed Bulent,YILMAZ ÜLKÜ,yalcin bulent The association of clinicopathologic features and peripheral blood parameters with high PD-L1 expression in non-small cell lung cancer. Tüberküloz ve Toraks 68, no.2 (2020): 118 - 125. 10.5578/tt.69182
MLA	BILGIN BURAK,Hizal Mutlu,Yücel Şebnem,Sendur Mehmet,Akyurek Nalan,Akinci Muhammed Bulent,YILMAZ ÜLKÜ,yalcin bulent The association of clinicopathologic features and peripheral blood parameters with high PD-L1 expression in non-small cell lung cancer. Tüberküloz ve Toraks, vol.68, no.2, 2020, ss.118 - 125. 10.5578/tt.69182
AMA	BILGIN B,Hizal M,Yücel Ş,Sendur M,Akyurek N,Akinci M,YILMAZ Ü,yalcin b The association of clinicopathologic features and peripheral blood parameters with high PD-L1 expression in non-small cell lung cancer. Tüberküloz ve Toraks. 2020; 68(2): 118 - 125. 10.5578/tt.69182
Vancouver	BILGIN B,Hizal M,Yücel Ş,Sendur M,Akyurek N,Akinci M,YILMAZ Ü,yalcin b The association of clinicopathologic features and peripheral blood parameters with high PD-L1 expression in non-small cell lung cancer. Tüberküloz ve Toraks. 2020; 68(2): 118 - 125. 10.5578/tt.69182
IEEE	BILGIN B,Hizal M,Yücel Ş,Sendur M,Akyurek N,Akinci M,YILMAZ Ü,yalcin b "The association of clinicopathologic features and peripheral blood parameters with high PD-L1 expression in non-small cell lung cancer." Tüberküloz ve Toraks, 68, ss.118 - 125, 2020. 10.5578/tt.69182
ISNAD	BILGIN, BURAK vd. "The association of clinicopathologic features and peripheral blood parameters with high PD-L1 expression in non-small cell lung cancer". Tüberküloz ve Toraks 68/2 (2020), 118-125. https://doi.org/10.5578/tt.69182